One-Shot gene therapy could reduce eye injections for millions
NCT ID NCT06196840
Summary
This study is testing whether a single gene therapy injection (LX102) can help control wet age-related macular degeneration, potentially reducing the need for frequent eye injections. It compares two doses of the experimental therapy against the current standard treatment in 50 people over one year. The main goal is to see if the gene therapy is safe and can maintain or improve vision while lasting longer between treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, China
-
Guangzhou Aier Eye Hospital
Guangzhou, China
-
Peking Union Medical College Hospital
Beijing, China
-
Shanghai Eye and ENT Hospital
Shanghai, China
-
Shanghai General Hospital
Shanghai, China
-
Shanxi Eye Hospital
Taiyuan, China
-
Tianjin Medical University Eye Hospital
Tianjin, China
-
West China Hospital of Sichuan University
Chengdu, China
-
Xuzhou No.1 People's Hospital
Xuzhou, China
-
Zhejiang University Eye Hospital
Hangzhou, Zhejiang, China
-
Zhongshan Ophthalmic Center of Sun Yat-Sen University
Guangzhou, China
Conditions
Explore the condition pages connected to this study.